- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 09.06. | NHS set for £30bn boost in spending review | ||
| 09.06. | Otsuka, Vera stake their claims to IgAN treatment | ||
| 06.06. | Bayer trial combines two top drugs for kidney disease | ||
| 06.06. | Digital health firm Omada Health prices $150m IPO | ||
| 06.06. | AZ claims EU approval for new Calquence regimens in CLL | ||
| 06.06. | Wockhardt has high hopes for novel antibiotic Zaynich | ||
| 05.06. | New auction for 23andMe sought with $305m bid from ex-CEO | ||
| 05.06. | Has mRNA delivered a breakthrough in quest for HIV cure? | ||
| 05.06. | NHS cleared to use Novo Nordisk's long-acting growth hormone | ||
| 05.06. | MHRA advises contraception for women taking 'skinny jabs' | ||
| 05.06. | EU: Trials should include pregnant subjects where possible | ||
| 05.06. | Neuralink raises $650m to widen use of brain implants | ||
| 04.06. | Ascletis says oral acne drug shows "exceptional efficacy" | ||
| 04.06. | Hims & Hers buys Zava to form European beachhead | ||
| 04.06. | MSD rumoured to be eyeing $3bn+ MoonLake takeover | ||
| 04.06. | ASCO 25: Sanofi hopes on-body delivery will boost Sarclisa | ||
| 04.06. | ASCO 25: J&J combo pill may see wider use in prostate cancer | ||
| 03.06. | Amid staff cuts, FDA looks to AI to 'optimise' reviews | ||
| 03.06. | ASCO 25: Enhertu bids for earlier use in HER2+ breast cancer | ||
| 02.06. | Consolidation in psychedelics as atai pairs with Beckley | ||
| 02.06. | BioNTech flips its cancer bispecific to BMS for a big profit | ||
| 02.06. | ASCO 25: AZ pitches upfront oral SERD use in breast cancer | ||
| 02.06. | 23andMe founder isn't giving up her bid to regain control | ||
| 02.06. | Sanofi draws up $9.1bn plan to buy Blueprint Medicines | ||
| 30.05. | Summit shrugs off survival miss with its VEGF bispecific |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .